Initiating drug therapy in multiple sclerosis patients: Effect on healthcare costs

American Journal of Pharmacy Benefits

Volumn 2, Issue 1, 2010, Pages 59-65

  Aforismo, John F ^a   Pill, Michael W ^b   Prescott, Jeff D ^b,c  

^a RJ Health Systems International LLC   (United States)

^b Gemini Healthcare LLC   (United States)

^c Clinical Care Targeted Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA1A INTERFERON; CORTICOSTEROID DERIVATIVE; GLATIRAMER; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SERVICE; MULTIPLE SCLEROSIS; PATIENT SELECTION; PRESCRIPTION; RETROSPECTIVE STUDY;

EID: 77953464934     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hauser SL, Goodkin DE. Multiple sclerosis and other demyelinating diseases. In: Braunwald E, Fauci AS, Kasper DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001:2452-2461.
2. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F; LORSEP Group. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008;15(9):916-921.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
4. Frohman EM. Multiple sclerosis. Med Clin N Am. 2003; 87(4):867-897, viii-ix.
5. Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med. 2006;73(1):91-102.
6. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007;68(5):326-337.
7. National Multiple Sclerosis Society. Epidemiology of MS. http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/ epidemiology-of-ms/index.aspx. Accessed April 13, 2009.
8. Wingerchuk DM, Weinshenker BG. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures. Neuroimaging Clin N Am. 2000;10(4):611-624, vii.
9. Bourdette DN, Prochazka AV, Mitchell W, Licari P, Burks J. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch Phys Med Rehabil. 1993;74(1):26-31.
10. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4(5):419-425.
11. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ. 1995;8:181-193.
12. Battaglia MA, Zagami P, Uccelli MM. A cost evaluation of multiple sclerosis. J Neurovirol. 2000;6(suppl 2):S191-S193.
13. Chin P, Laouri M, Broder M, Langer-Gould A, Smith C. Healthcare utilisation among insured multiple sclerosis patients in the U.S. from 2005-2006 [abstract]. Mult Scler. 2007;13(suppl 2):S19-S132.
14. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44-52.
15. Symmetry Health. An overview of Symmetry Episode Treatment Groups (ETGs). http://www.symmetry-health.com/products/product-SETG.php. Accessed April 13, 2009.
16. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702.
17. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469-476.
18. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-261.